There are many modified molecules of glucagon that had the property to inhibit the function of glucagon receptors, thus preventing the hyperglucagonemia-induced hyperglycemia seen in diabetes [29]; however, the association of glucagon with abdominal obesity has been sparsely researched, and only a few studies are available. The gene discussed is GCGR; the disease is Abdominal obesity.